FLOW
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is FLOW?
Semaglutide 1 mg weekly in chronic kidney disease with type 2 diabetes (NEJM 2024).
Its combined kidney endpoint, counting eGFR decline, kidney failure, and renal or CV death, fell 24% (HR 0.76).
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where FLOW comes up on this site
On GLP Watchdog, FLOW comes up in 1 research article and 1 tool.
Research that discusses it
Tools that use it
Connected terms
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers